Preconditioning, anesthetics, and perioperative medication

Best Practice and Research: Clinical Anaesthesiology

Volumn 22, Issue 1, 2008, Pages 151-165

  Shim, Yon Hee ^a   Kersten, Judy R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

COX 2 antagonists; diabetes; ischemic preconditioning; KATP channels; opioids; sulfonylureas; volatile anesthetics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 HYDROXYDECANOIC ACID; ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DESFLURANE; ENFLURANE; ETOMIDATE; FENTANYL; FENTANYL ISOTHIOCYANATE; FLUMAZENIL; GLIBENCLAMIDE; HALOTHANE; INHALATION ANESTHETIC AGENT; INSULIN; INTRAVENOUS ANESTHETIC AGENT; ISOFLURANE; KETAMINE; MIDAZOLAM; MORPHINE; OPIATE DERIVATIVE; PLACEBO; PROPOFOL; PROSTANOID; REMIFENTANIL; SEVOFLURANE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNINDEXED DRUG;

ANESTHESIA; AORTA CLAMPING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG CONTRAINDICATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC PRECONDITIONING; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANESTHETICS, INTRAVENOUS; ANIMALS; CARDIOMYOPATHIES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; PERIOPERATIVE CARE; POTASSIUM CHANNELS; PREANESTHETIC MEDICATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; SULFONYLUREA COMPOUNDS;

EID: 40949095170     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2007.08.003     Document Type: Review

References (89)

1. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
2. Baxter G.F., Goma F.M., and Yellon D.M. Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium. Basic Research in Cardiology 92 (1997) 159-167
3. Zhao Z.Q., Corvera J.S., Halkos M.E., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. American Journal of Physiology. Heart and Circulatory Physiology 285 (2003) H579-H588
4. Bland J.H., and Lowenstein E. Halothane-induced decrease in experimental myocardial ischemia in the non-failing canine heart. Anesthesiology 45 (1976) 287-293
5. Davis R.F., DeBoer L.W., Rude R.E., et al. The effect of halothane anesthesia on myocardial necrosis, hemodynamic performance, and regional myocardial blood flow in dogs following coronary artery occlusion. Anesthesiology 59 (1983) 402-411
6. Warltier D.C., al-Wathiqui M.H., Kampine J.P., and Schmeling W.T. Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiology 69 (1988) 552-565
7. Kersten J.R., Schmeling T.J., Pagel P.S., et al. Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 87 (1997) 361-370
8. Kevin L.G., Novalija E., Riess M.L., et al. Sevoflurane exposure generates superoxide but leads to decreased superoxide during ischemia and reperfusion in isolated hearts. Anesthesia and Analgesia 96 (2003) 949-955
9. Tanaka K., Weihrauch D., Kehl F., et al. Mechanism of preconditioning by isoflurane in rabbits: a direct role for reactive oxygen species. Anesthesiology 97 (2002) 1485-1490
10. Ludwig L.M., Weihrauch D., Kersten J.R., et al. Protein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species. Anesthesiology 100 (2004) 532-539
11. Toller W.G., Kersten J.R., Gross E.R., et al. Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins. Anesthesiology 92 (2000) 1400-1407
12. Toma O., Weber N.C., Wolter J.I., et al. Desflurane preconditioning induces time-dependent activation of protein kinase C epsilon and extracellular signal-regulated kinase 1 and 2 in the rat heart in vivo. Anesthesiology 101 (2004) 1372-1380
13. Novalija E., Varadarajan S.G., Camara A.K., et al. Anesthetic preconditioning: triggering role of reactive oxygen and nitrogen species in isolated hearts. American Journal of Physiology. Heart and Circulatory Physiology 283 (2002) H44-H52
14. Chiari P.C., Bienengraeber M.W., Weihrauch D., et al. Role of endothelial nitric oxide synthase as a trigger and mediator of isoflurane-induced delayed preconditioning in rabbit myocardium. Anesthesiology 103 (2005) 74-83
15. Mullenheim J., Ebel D., Frassdorf J., et al. Isoflurane preconditions myocardium against infarction via release of free radicals. Anesthesiology 96 (2002) 934-940
16. Ludwig L.M., Tanaka K., Eells J.T., et al. Preconditioning by isoflurane is mediated by reactive oxygen species generated from mitochondrial electron transport chain complex III. Anesthesia and Analgesia 99 (2004) 1308-1315
17. Riess M.L., Eells J.T., Kevin L.G., et al. Attenuation of mitochondrial respiration by sevoflurane in isolated cardiac mitochondria is mediated in part by reactive oxygen species. Anesthesiology 100 (2004) 498-505
18. Venkatapuram S., Wang C., Krolikowski J.G., et al. Inhibition of apoptotic protein p53 lowers the threshold of isoflurane-induced cardioprotection during early reperfusion in rabbits. Anesthesia and Analgesia 103 (2006) 1400-1405
19. Krolikowski J.G., Weihrauch D., Bienengraeber M., et al. Role of Erk1/2, p70s6 K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo. Canadian Journal of Anaesthesia 53 (2006) 174-182
20. Di Lisa F., and Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovascular Research 70 (2006) 191-199
21. Pagel P.S., Krolikowski J.G., Neff D.A., et al. Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesthesia and Analgesia 102 (2006) 1348-1354
22. Krolikowski J.G., Bienengraeber M., Weihrauch D., et al. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesthesia and Analgesia 101 (2005) 1590-1596
23. Alcindor D., Krolikowski J.G., Pagel P.S., et al. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacological preconditioning in vivo. Anesthesiology 100 (2004) 547-554
24. Tanaka K., Ludwig L.M., Krolikowski J.G., et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology 100 (2004) 525-531
25. + channels reconstituted in lipid bilayers. American Journal of Physiology. Heart and Circulatory Physiology 284 (2003) H1865-H1871
26. Kohro S., Hogan Q.H., Nakae Y., et al. Anesthetic effects on mitochondrial ATP-sensitive K channel. Anesthesiology 95 (2001) 1435-1440
27. Zaugg M., Lucchinetti E., Spahn D.R., et al. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology 97 (2002) 4-14
28. + channels modulate cardiac mitochondrial function. American Journal of Physiology. Heart and Circulatory Physiology 275 (1998) H1567-H1576
29. Hausenloy D., and Yellon D. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovascular Research 61 (2004) 448-460
30. 2+ overload during ischemia in Guinea pig intact hearts: reversal by 5-hydroxydecanoic acid. Anesthesia and Analgesia 95 (2002) 1540-1546
31. Crompton M. The mitochondrial permeability transition pore and its role in cell death. The Biochemical Journal 341 Pt 2 (1999) 233-249
32. Piriou V., Chiari P., Gateau-Roesch O., et al. Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology 100 (2004) 581-588
33. Gross E.R., and Gross G.J. Ligand triggers of classical preconditioning and postconditioning. Cardiovascular Research 70 (2006) 212-221
34. Patel H.H., Ludwig L.M., Fryer R.M., et al. Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K(ATP) channel opening. The FASEB Journal 16 (2002) 1468-1470
35. Bell S.P., Sack M.N., Patel A., et al. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. Journal of the American College of Cardiology 36 (2000) 2296-2302
36. Gross E.R., Peart J.N., Hsu A.K., et al. Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. American Journal of Physiology. Heart and Circulatory Physiology 288 (2005) H2744-H2749
37. Ludwig L.M., Patel H.H., Gross G.J., et al. Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors. Anesthesiology 98 (2003) 705-711
38. Weihrauch D., Krolikowski J.G., Bienengraeber M., et al. Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesthesia and Analgesia 101 (2005) 942-949
39. Kokita N., Hara A., Abiko Y., et al. Propofol improves functional and metabolic recovery in ischemic reperfused isolated rat hearts. Anesthesia and Analgesia 86 (1998) 252-258
40. Kokita N., and Hara A. Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart. Anesthesiology 84 (1996) 117-127
41. Sztark F., Ichas F., Ouhabi R., et al. Effects of the anaesthetic propofol on the calcium-induced permeability transition of rat heart mitochondria: direct pore inhibition and shift of the gating potential. FEBS Letters 368 (1995) 101-104
42. Cason B.A., Gamperl A.K., Slocum R.E., and Hickey R.F. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology 87 (1997) 1182-1190
43. Kawano T., Oshita S., Tsutsumi Y., et al. Clinically relevant concentrations of propofol have no effect on adenosine triphosphate-sensitive potassium channels in rat ventricular myocytes. Anesthesiology 96 (2002) 1472-1477
44. Mullenheim J., Frassdorf J., Preckel B., et al. Ketamine, but not S(+)-ketamine, blocks ischemic preconditioning in rabbit hearts in vivo. Anesthesiology 94 (2001) 630-636
45. Mullenheim J., Rulands R., Wietschorke T., et al. Late preconditioning is blocked by racemic ketamine, but not by S(+)-ketamine. Anesthesia and Analgesia 93 (2001) 265-270
46. Ko S.H., Lee S.K., Han Y.J., et al. Blockade of myocardial ATP-sensitive potassium channels by ketamine. Anesthesiology 87 (1997) 68-74
47. Zaugg M., Lucchinetti E., Spahn D.R., et al. Differential effects of anesthetics on mitochondrial K(ATP) channel activity and cardiomyocyte protection. Anesthesiology 97 (2002) 15-23
48. Hanouz J.L., Zhu L., Persehaye E., et al. Ketamine preconditions isolated human right atrial myocardium: roles of adenosine triphosphate-sensitive potassium channels and adrenoceptors. Anesthesiology 102 (2005) 1190-1196
49. Rivo J., Raphael J., Drenger B., et al. Flumazenil mimics whereas midazolam abolishes ischemic preconditioning in a rabbit heart model of ischemia-reperfusion. Anesthesiology 105 (2006) 65-71
50. Riess M.L., Camara A.K., Rhodes S.S., et al. Increasing heart size and age attenuate anesthetic preconditioning in guinea pig isolated hearts. Anesthesia and Analgesia 101 (2005) 1572-1576
51. Lakatta E.G., and Sollott S.J. Perspectives on mammalian cardiovascular aging: humans to molecules. Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology 132 (2002) 699-721
52. Juhaszova M., Zorov D.B., Kim S.H., et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. The Journal of Clinical Investigation 113 (2004) 1535-1549
53. Kehl F., Krolikowski J.G., Mraovic B., et al. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 96 (2002) 183-188
54. Tanaka K., Kehl F., Gu W., et al. Isoflurane-induced preconditioning is attenuated by diabetes. American Journal of Physiology. Heart and Circulatory Physiology 282 (2002) H2018-H2023
55. Gross E.R., Hsu A.K., and Gross G.J. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 56 (2007) 127-136
56. Kersten J.R., Montgomery M.W., Ghassemi T., et al. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. American Journal of Physiology. Heart and Circulatory Physiology 280 (2001) H1744-H1750
57. Belhomme D., Peynet J., Louzy M., et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 100 (1999) II340-II344
58. Penta de Peppo A., Polisca P., Tomai F., et al. Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. The Annals of Thoracic Surgery 68 (1999) 112-118
59. Tomai F., De Paulis R., Penta de Peppo A., et al. Beneficial impact of isoflurane during coronary bypass surgery on troponin I release. Giornale Italiano di Cardiologia 29 (1999) 1007-1014
60. Haroun-Bizri S., Khoury S.S., Chehab I.R., et al. Does isoflurane optimize myocardial protection during cardiopulmonary bypass?. Journal of Cardiothoracic Vascular Anesthesia 15 (2001) 418-421
61. Nader N.D., Li C.M., Khadra W.Z., et al. Anesthetic myocardial protection with sevoflurane. Journal of Cardiothoracic Vascular Anesthesia 18 (2004) 269-274
62. Lee M.C., Chen C.H., Kuo M.C., et al. Isoflurane preconditioning-induced cardio-protection in patients undergoing coronary artery bypass grafting. European Journal of Anaesthesiology 23 (2006) 841-847
63. Conzen P.F., Fischer S., Detter C., and Peter K. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery. Anesthesiology 99 (2003) 826-833
64. Pouzet B., Lecharny J.B., Dehoux M., et al. Is there a place for preconditioning during cardiac operations in humans?. The Annals of Thoracic Surgery 73 (2002) 843-848
65. Julier K., da Silva R., Garcia C., et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 98 (2003) 1315-1327
66. Lucchinetti E., Hofer C., Bestmann L., et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology 106 (2007) 444-457
67. De Hert S.G., ten Broecke P.W., Mertens E., et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 97 (2002) 42-49
68. De Hert S.G., Cromheecke S., ten Broecke P.W., et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology 99 (2003) 314-323
69. De Hert S.G., Van der Linden P.J., Cromheecke S., et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 101 (2004) 9-20
70. De Hert S.G., Van der Linden P.J., Cromheecke S., et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 101 (2004) 299-310
71. Cromheecke S., Pepermans V., Hendrickx E., et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesthesia and Analgesia 103 (2006) 289-296
72. Garcia C., Julier K., Bestmann L., et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. British Journal of Anaesthesia 94 (2005) 159-165
73. Fellahi J.L., Gue X., Philippe E., et al. Isoflurane may not influence postoperative cardiac troponin I release and clinical outcome in adult cardiac surgery. European Journal of Anaesthesiology 21 (2004) 688-693
74. Law-Koune J.D., Raynaud C., Liu N., et al. Sevoflurane-remifentanil versus propofol-remifentanil anesthesia at a similar bispectral level for off-pump coronary artery surgery: no evidence of reduced myocardial ischemia. Journal of Cardiothoracic Vascular Anesthesia 20 (2006) 484-492
75. Guarracino F., Landoni G., Tritapepe L., et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. Journal of Cardiothoracic Vascular Anesthesia 20 (2006) 477-483
76. Bein B., Renner J., Caliebe D., et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesthesia and Analgesia 100 (2005) 610-616
77. Symons J.A., and Myles P.S. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. British Journal of Anaesthesia 97 (2006) 127-136
78. Kehl F., Krolikowski J.G., Mraovic B., et al. Is isoflurane-induced preconditioning dose related?. Anesthesiology 96 (2002) 675-680
79. Murphy G.S., Szokol J.W., Marymont J.H., et al. Opioids and cardioprotection: the impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass. Journal of Cardiothoracic Vascular Anesthesia 20 (2006) 493-502
80. Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 supplementry (1970) 789-830
81. Forlani S., Tomai F., De Paulis R., et al. Preoperative shift from glibenclamide to insulin is cardioprotective in diabetic patients undergoing coronary artery bypass surgery. Journal of Cardiovascular Surgery 45 (2004) 117-122
82. Lee T.M., and Chou T.F. Impariment of myocardial protection in type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 531-537
83. Gu W., Pagel P.S., Warltier D.C., and Kersten J.R. Modifying cardiovascular risk in diabetes mellitus. Anesthesiology 98 (2003) 774-779
84. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. American Journal of Cardiology 92 (2003) 34J-41J
85. Yue T., Chen J., Bao W., et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-y agonist rosiglitazone. Circulation 104 (2001) 2588-2594
86. Wayman N.S., Hattori Y., McDonald M.C., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. The FASEB Journal 16 (2002) 1027-1040
87. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 356 (2007) 2457-2471
88. Ott E., Nussmeier N.A., Duke P.C., et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery 125 (2003) 1481-1492
89. Furberg C.D., Psaty B.M., and FitzGerald G.A. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 111 (2005) 249